Revive Therapeutics Ltd (RVVTF)

[Fress]

International Trial's will Focus on Bucillamine in the treatment of Covid-19
§ Well-known safety profile and prescribed for arthritis in Japan and South Korea for over 30 years
§ Revive’s clinical history with Bucillamine
§ Obtained 2 FDA INDs with Bucillamine and FDA orphan drug status
§ FDA Phase 2 clinical study for acute gout flares and cystinuria
§ Bucillamine (BUC) scientific rationale as an intervention for COVID-19 (see Appendix)
§ BUC is 16x more potent than particularly N-acetylcysteine (NAC); NAC has shown to prevent acute lung
injury caused by influenza virus
§ BUC shown superior function in restoring glutathione and therefore greater potential to prevent acute
lung injury during influenza infection
§ BUC also shown to prevent oxidative and reperfusion injury in heart and liver tissues
§ BUC proven safety and MOA similar to NAC, but with much higher potency
§ Advancing towards FDA Phase 3 clinical study for COVID-19

--------------------------------------------------------------------
Why I doubled my position: Dr David Boulware leading the bucillamine Trials. He is a leading expert in the field. You need to follow the bread crumbs!

1 of 4 Drugs commencing phase 3 Trials in the USA. NVAX vaccine isn't even phase 3 Yet. Vaccines and Anti Virals have lots of Side effects thats why Bucillamine stands out. Very low side effects with favorable results used for 30 years in Japan and South Korea who are usually a step ahead of all countries in remedies.

And the company is funded through 2021.


Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19.


TORONTO, March 24, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company, is pleased to announce that Dr. David Boulware, MD, MPH, CTropMed, FIDSA, will join the Company as a Scientific Advisor to guide on the Company’s current and future clinical programs including its research and development strategy for infectious diseases, including the coronavirus disease (“COVID-19”).

Dr. Boulware is an infectious disease physician-scientist and Professor of Medicine, Division of Infectious Diseases and International Medicine at The University of Minnesota. Dr. Boulware is currently the Principal Investigator of a globally recognized COVID-19 clinical trial to determine if post-exposure prophylaxis with hydroxychloroquine can prevent progression development of symptomatic COVID-19 disease after known exposure to the SARS-CoV2 virus (ClinicalTrials.gov Identifier: NCT04308668). His primary research interests are in meningitis in resource-limited areas including diagnosis, prevention, treatment, and quality improvement initiatives incorporating cost-effectiveness analyses in order to translate knowledge into improved care. Dr. Boulware’s current research is focused on improving the clinical outcomes of HIV-infected persons with cryptococcal meningitis and TB meningitis. Dr. Boulware has active research collaborations in Uganda, South Africa, and Ethiopia leading a multidisciplinary, international research team. He serves on US and WHO panels for cryptococcal meningitis and WHO panels for advanced HIV disease.

“We are pleased to have Dr. Boulware join us to assist in advancing the research and clinical development of our infectious disease initiatives including exploring the use of Bucillamine as a potential novel treatment for COVID-19," said Michael Frank, Chief Executive Officer of Revive. "Dr. Boulware brings comprehensive clinical expertise in infectious diseases and he will be valuable in guiding our clinical development strategy and product pipeline in infectious diseases."

“I am excited to assist Revive in their objective in pursuing the clinical development of Bucillamine for infectious diseases and its prospect as a potential solution for COVID-19,” said Dr. Boulware.

As previously announced, the Company is exploring the use of Bucillamine as a potential novel treatment for infectious diseases including COVID-19. The Company has applied for a provisional patent with the U.S. Patent and Trademark Office entitled “Use of Bucillamine in the Treatment of Infectious Diseases” (Serial No. 62/991,996). Revive plans to file an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for the use of Bucillamine in the treatment of COVID-19. Parts of the IND will be supported and referenced by the Company’s previous INDs accepted by the FDA and its Phase II grant for the clinical investigation of Bucillamine in the treatment of acute gout flares and cystinuria.



https://www.biospace.com/article/releases/revive-therapeutics-appoints-dr-david-boulware-md-as-scientific-advisor-for-infectious-diseases-including-covid-19/


$RVVTF